Latest News and Press Releases
Want to stay updated on the latest news?
-
SAN RAMON, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
-
SAN RAMON, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
-
NeuVax™ (nelipepimut-S) Phase 3, PRESENT clinical trial reaches 70th qualifying disease free survival eventPRESENT Interim safety and futility analysis expected at the end of Q2$23.4 million in net...
-
SAN RAMON, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
-
SAN RAMON, Calif., April 26, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
-
SAN RAMON, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
-
SAN RAMON, Calif., March 29, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
-
SAN RAMON, Calif., March 11, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
-
Two Key Milestones in the NeuVax™ (nelipepimut-S) Phase 3, PRESENT Clinical Trial Expected in 1H, 2016Webcast and conference call scheduled for today at 2:00 p.m. P.T. / 5:00 p.m. E.T. SAN RAMON,...
-
SAN RAMON, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...